Back to Search Start Over

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies.

Authors :
Elitzur S
Shiloh R
Loeffen JLC
Pastorczak A
Takagi M
Bomken S
Baruchel A
Lehrnbecher T
Tasian SK
Abla O
Arad-Cohen N
Astigarraga I
Ben-Harosh M
Bodmer N
Brozou T
Ceppi F
Chugaeva L
Dalla Pozza L
Ducassou S
Escherich G
Farah R
Gibson A
Hasle H
Hoveyan J
Jacoby E
Jazbec J
Junk S
Kolenova A
Lazic J
Lo Nigro L
Mahlaoui N
Miller L
Papadakis V
Pecheux L
Pillon M
Sarouk I
Stary J
Stiakaki E
Strullu M
Tran TH
Ussowicz M
Verdu-Amoros J
Wakulinska A
Zawitkowska J
Stoppa-Lyonnet D
Taylor AM
Shiloh Y
Izraeli S
Minard-Colin V
Schmiegelow K
Nirel R
Attarbaschi A
Borkhardt A
Source :
Blood [Blood] 2024 Sep 12; Vol. 144 (11), pp. 1193-1205.
Publication Year :
2024

Abstract

Abstract: Ataxia-telangiectasia (A-T) is an autosomal-recessive disorder caused by pathogenic variants (PVs) of the ATM gene, predisposing children to hematological malignancies. We investigated their characteristics and outcomes to generate data-based treatment recommendations. In this multinational, observational study we report 202 patients aged ≤25 years with A-T and hematological malignancies from 25 countries. Ninety-one patients (45%) presented with mature B-cell lymphomas, 82 (41%) with acute lymphoblastic leukemia/lymphoma, 21 (10%) with Hodgkin lymphoma and 8 (4%) with other hematological malignancies. Four-year overall survival and event-free survival (EFS) were 50.8% (95% confidence interval [CI], 43.6-59.1) and 47.9% (95% CI 40.8-56.2), respectively. Cure rates have not significantly improved over the last four decades (P = .76). The major cause of treatment failure was treatment-related mortality (TRM) with a four-year cumulative incidence of 25.9% (95% CI, 19.5-32.4). Germ line ATM PVs were categorized as null or hypomorphic and patients with available genetic data (n = 110) were classified as having absent (n = 81) or residual (n = 29) ATM kinase activity. Four-year EFS was 39.4% (95% CI, 29-53.3) vs 78.7% (95% CI, 63.7-97.2), (P < .001), and TRM rates were 37.6% (95% CI, 26.4-48.7) vs 4.0% (95% CI, 0-11.8), (P = .017), for those with absent and residual ATM kinase activity, respectively. Absence of ATM kinase activity was independently associated with decreased EFS (HR = 0.362, 95% CI, 0.16-0.82; P = .009) and increased TRM (hazard ratio [HR] = 14.11, 95% CI, 1.36-146.31; P = .029). Patients with A-T and leukemia/lymphoma may benefit from deescalated therapy for patients with absent ATM kinase activity and near-standard therapy regimens for those with residual kinase activity.<br /> (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Details

Language :
English
ISSN :
1528-0020
Volume :
144
Issue :
11
Database :
MEDLINE
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
38917355
Full Text :
https://doi.org/10.1182/blood.2024024283